Recorded Presentations from the NCCN 2025 Lung Cancer Congress

This congress focuses on providing education for the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Guidelines, novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care. 

New Targeted Therapies for Non-Small Cell Lung Cancer
The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.
NCCN Guidelines® Updates: Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Archived NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer.

NCCN Optimizing Patient Outcomes - Hitting the Right Target: Updates in Biomarker-Directed Therapy for Non-Small Cell Lung Cancer

NSCLC is a complex disease with many variables to consider for systemic therapy selection, including the rapidly growing number of predictive biomarkers.

New Targeted Therapies for Metastatic Non-Small Cell Lung Cancer (JA copy)
Clinicians need to be aware of the most recent recommendations about biomarker testing and the appropriate use of new targeted therapies (including sequencing these therapies, assessing and managing side effects from these therapies), so they can select the most appropriate therapy for their patients with metastatic NSCLC.
NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer.

NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic co

NCCN Guidelines® Insights - Small Cell Lung Cancer, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment.

Pages

Subscribe to RSS - Lung Cancers